Purpose Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. Methods Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133?), AR amplification and PTEN status was identified. Results The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score C7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p \ 0.05). CD133 was expressed in 69 (96%) patients. The median CD133? expression in circulating tumor cells CTCs was higher among the 21 AR-V7 positive cases versus AR-V7 negative (7 vs. 3). Androgen Receptor and PTEN fluorescence in situ hybridization (FISH) on CD133? captured cells were performed: 37 cases showed Cfour CD133? CTCs, of which 81% showed an increased AR copy number. This percentage was similar in both AR-V7-positive and AR-V7-negative patients. A total of 68% of the cases showed deletion of PTEN: 70% were ARV-7 positive vs. 67%, which were AR-V7 negative. Conclusions Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nanoimmunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.
Introduction
Prostate cancer is an androgen-dependent malignant tumor. However, after an initial response to androgen deprivation therapy (ADT), patients with advanced disease will develop castration-resistant prostate cancer (CRPC), a latestage of the disease, which is associated with worse prognosis. Multiple adaptation processes such as androgen receptor (AR) gene amplification, AR gene mutation, alternative splice variants or alternative AR activation through bypass pathways [1] allow persistent activation of androgen receptor (AR) signaling pathways in CRPC. The past decade has seen the rapid development of several agents for CRPC, which has resulted in improved overall survival. These newer therapeutic agents have not been compared with each other. Therefore, the best sequence remains unclear and new biomarkers are urgently needed to guide treatment decisions. Because mutations in the AR gene are an escape mechanism that can lead to CRPC, these mutations have been examined in circulating tumor cells (CTCs). Indeed, patients whose CTCs tested positive for AR splice variant 7 (AR-V7), a truncated form of the AR, were found to be resistant to enzalutamide and abiraterone. This finding could make AR-V7 a marker for treatment selection [2] . On the other hand, CD133-a glycoprotein associated with stem cell and migratory properties and vasculogenic mimicry circulating tumor cells-has been used as a stem cell biomarker identifying infrequent prostate epithelial progenitor cells that play a role in development and tumor biology. Recent studies have demonstrated that CD133? CTCs are present in patients with advanced prostate cancer, thus providing greater proliferative potential compared to CD133 negative cells [3, 4] . Taking serial biopsies to capture changes in tumor biology may be troublesome for patients. Furthermore, a single biopsy may not represent the heterogeneity of the disease. Taking a liquid biopsy at different timepoints may be an opportunity to perform this serial assessment without patient discomfort. CTCs can be obtained from a non-invasive routine blood test. Indeed, the CTC count number has emerged as an important prognostic tool in CRPC [5] . Even more promising than enumeration of CTCs is the ability to molecularly characterize these CTCs [6] . Validation of potential biomarkers in blood is difficult because blood contains proteins from many tissue sources in small concentrations and these proteins are under numerous mechanisms for blood clearance. For this reason, novel technology based on automated capillary nano-immunoassay (CNIA) has been developed [7] . The WES TM system (ProteinSimple) enables a rapid and quantitative analysis of specific proteins from small quantities of sample (dependent on cell size and percentage of protein). Uniquely, the system can examine numerous proteins from a small cell sample as it requires very small amounts (as low as 80 ng) of protein per capillary. The aim of this study was to evaluate and validate the presence of AR-V7 in plasma from patients with different stages of prostate cancer using the WES TM platform. Firstly, we used the WES TM platform on prostate cancer cell lines to standardize the assays for determining AR-V7. The association between AR-V7 with stem cell biomarkers (such as CD133?) and genomic changes in these CTCs (AR amplification and PTEN status) was also investigated.
Materials and methods

Design and variables
This was an exploratory study to evaluate and validate the presence of AR-V7 in the plasma of prostate cancer patients. The design of this study comprised evaluation of the presence of AR-V7 assessed by TM WES TM in different groups of samples (prostate cancer cell lines, plasma of healthy donors and plasma from patients with prostate cancer). Then, the correlation of the results with clinical characteristics of the patients, expression of CD133 in CTCs, AR amplification and PTEN status was analyzed. Patient clinical characteristics, such as age, serum PSA level, Gleason score and metastatic sites were collected.
Patients
Patients with either localized or advanced prostate cancer were eligible for the study. The samples of patients with localized prostate cancer were extracted before the radical treatment (prostatectomy or radiotherapy). Men with metastatic prostate cancer could have received standard-of-care therapy with ADT (LHRH agonists ± peripheral antiandrogen therapy), abiraterone, enzalutamide, chemotherapy (docetaxel, cabazitaxel) or corticosteroids. Both castrationsensitive and castration-resistant patients were eligible. In those patients with advanced disease, samples were collected before or during the course of therapy. The study was carried out in accordance with the ethical standards of the Declaration of Helsinki and was approved by the Institutional Review Board of the University Hospital of Salamanca (Spain). Written informed consent was obtained from each patient before any study-specific procedure was conducted.
Samples
Whole blood (10 ml) was collected and processed in EDTA tubes. Within 1 h of collection, plasma was removed after centrifugation at 1600 rpm at 4°C (2 9 10 min) and stored in 1 ml aliquots at -80°C. The peripheral blood mononuclear cells (PBMC) were used for fluorescence-activated cell sorting (FACS).
Western blot
The human prostate cell lines PC3 and VCaP (ATCC, Manassas, VA, USA) were used to standardize the assays for AR-V7 through the WES TM platform. Cell lines were grown in recommended media and maintained in a humidified 5% CO 2 incubator at 37°C. For Western Blot analysis, the cells were lysed in RIPA buffer (Santa Cruz Biotech. USA) supplemented with protease and phosphates inhibitors (Roche). Then, 8% SDS-PAGE was performed followed by protein transfer on nitrocellulose membrane. Next, the membranes were blocked in 5% non-fat milk in PBS with 1% TWEEN 20 and incubated over night at 4°C with appropriate antibodies (AR-V7 1:1000 Abcam USA; AR 1:1000 Santa Cruz Biotech. USA; GAPDH 1:50,000, Novusbio USA). Next day, the membranes were incubated with appropriate secondary antibody conjugated with Alexa-780, washed 3 times in PBS with 1% TWEEN 20 and visualized in LI-COR Odyssey scanner. Then, blood samples from eleven healthy donors were analyzed.
Capillary electrophoresis immunoassay
Capillary electrophoresis immunoassay or SimpleWestern analyses were performed using the WES TM machine (ProteinSimple Santa Clara, CA) according to the manufacturer's protocol. With this technique, proteins are separated by size, immobilised and probed with specific antibodies. Signal intensity is detected by a horseradish peroxidase-conjugated chemiluminescence system and the data are shown as an electropherogram. In brief, 4.8 ll of 1:100 pre-diluted plasma samples in 0.19 Sample Buffer (ProteinSimple) was mixed with a master mix (ProteinSimple) to a final concentration of 19 sample buffer, 19 fluorescent molecular weight markers and 40 mM dithiothreitol (DTT) and then heated at 950°C for 5 min. The samples, blocking reagent, wash buffer, primary antibody, secondary antibody and chemiluminescent substrate were dispensed into designated wells in the manufacturerprovided microplate. After plate loading, the separation electrophoresis and immunodetection steps took place in the capillary system and were fully automated. Simple Western analysis was carried out at room temperature. The primary antibody used was AR-V7 (Abcam ab198394). The data were analyzed by Compass Software. Quantitative analysis for AR-V7 protein peak was done automatically as area under the peak.
Fluorescence-activated cell sorting (flow cytometry)
For FACS (FACSAria, BD Biosciences, San Jose, CA, USA), the PBMC were subjected to erythrocyte lysis using NH4CL 0.38% ammonium chloride for 30 min on RT (dilution 2:20 ml). Then, the suspension was washed in Ca free phosphate-buffered saline (PBS) supplemented with 1% FBS were labeled with the antibody (approximately 1 lg/106 cells) for 30 min on ice. Cell fluorescence was sorted and analyzed with the FACS Aria sorter (Becton-Dickinson, New Jersey, USA) and FACSDiVa software (Becton-Dickinson Biosciences (BDB). The acquisition was performed in two consecutive steps. In the first step, 50,000 cells corresponding to the total cellularity were acquired; and in the second step, only the information on CD133? cells was stored to increase assay sensitivity. Then, CD34-, CD133? and CD45-events were selected and separated into an Eppendorf tube containing methanol: acetic (3/1) for further studies.
In situ hybridization
In the CD133? enriched fraction of the FACS sorted samples, FISH analysis was performed for AR-LSI [Androgen Receptor Gene (Xq12)] and PTEN (PTEN/CEP10) (Vysis ProVysion, Abbott Molecular Inc.). The cell suspensions were dropped on cold and wet slides and left to dry at room temperature overnight. FISH was carried out according to the manufacturer's protocol. Probes were placed on slides, sealed with rubber cement and incubated at 37°C in a moisture chamber overnight. After washing, the slides were mounted in Vectashield antifade solution (Vector Laboratories, Burlingame, CA, USA). The slides were coded and stored at 4°C in the dark until analysis. The automated scanning system Metafer 4, Version 3.2.1, from MetaSystems (Atlussheim, Germany) with a motorized Axio Imager Z1 microscope (Carl Zeiss, Germany) was used for scanning, classifying and detecting cells under fluorescent illumination. A minimum of FISH results on four CTCs was required to ensure that the result was technically reproducible.
Statistical analysis
Statistical analysis was performed with the SPSS v23.0 (IBM-SPSS). All statistical tests were two-sided, and p B 0.05 was considered significant. Statistical analysis compared categorical parameters and clinicopathologic features by the Chi-square test. Median were compared by non-parametric test (Mann-Whitney U test).
Results
Assay setup
To show the antibody specificity, we used cell lines whose expression of the AR-V7 isoform was previously known:
VCaP [8] as positive control and PC3 as negative control [9] . The specificity of AR-V7 antibody was tested by standard Western Blot. As shown in Fig. 1 , only one band corresponding to AR-V7 was detected in positive control. Subsequently, capillary Electrophoresis Immunoassay detected no AR-V7 signal for PC3 cells even using high antibody concentration, as shown in Fig. 2a . On the other side, a strong, specific peak was observed for VCaP cell lines. Using this cell line, we were able to titrate the antibody for saturation and determined the antibody dilution to be used at 1:50. The peak detected corresponded to the MW about 97 kDa in size-CNIA (Fig. 2b) . We then performed the titration using serial dilution of two samples and the average peak area was quantified for each dilution. Linear regression analysis confirmed that the assay is linear from 250,000 to 2000 AU of peak area of chemiluminescence (Fig. 2c) .
Serum samples analysis
Since human serum contains a high concentration of proteins, we pre-diluted the samples in 0.19 Sample Buffer provided in the kit. All analyses were done automatically in the WES TM system, detecting previously established peaks of AR-V7 protein in serum samples at migration in capillaries that corresponded to a size around 97 kDa. To allow the standardization between each capillary and between distinct runs, the system control (SC) antibody was used as well. The peak from the SC was used to automatically normalize the AR-V7 signal in each capillary. As previously established, the limit of detection was around 2000 AU; thus, any signal below this value was considered as negative (Fig. 3) .
Blood samples from eleven healthy donors were analyzed to establish the presence or absence of this protein in blood. No cases of previously established peaks of AR-V7 protein that correspond to a size around 97 kDa were detected.
From January 2014 to November 2015, 72 patients with localized or advanced prostate cancer who were treated at the University Hospital of Salamanca were enrolled in the study. AR-V7 signal was detected in 21 cases (29%). Fiftyone samples (71%) were considered as negative. The clinical characteristics of these patients, shown by AR-V7 expression, are described in Table 1 . Of the 21 patients with expression positive for AR-V7, a Gleason score C7 was observed in 17 patients (81%), 15 had CRPC (71%) and 18 (86%) had metastatic disease. Only PSA median was statistically significant associated with ARV7? (p \ 0.05).
AR-V7 and CD133
We found CD133 to be expressed in CTCs from 69 of 72 patients (96%). The median of the CD133? cell number was 4 (range 1-1922) in a median of 20 9 10 6 sorting cells. In half of patients, the number of CD133? CTCs was higher than the median [37/72 (51%) C 4], and the number of CD133? CTCs was C4. Three cases did not show CD133? expression in their CTCs (two cases of metastatic CRPC and one case of castration-sensitive prostate cancer). The median CD133? CTCs of the 21 AR-V7? cases were 7 (range 1-81), whereas in AR-V7-negative cases (51 cases), the median CD133? was 3 (range 0-1922). The number of cases with more than 4 CD133? CTCs was higher in the AR-V7? tumors compared with AR-V7-negative tumors (66 Vs. 47%).
In situ hybridization
In the FISH analysis, the number of signals observed on the total of the separate cells (hybridized to AR and PTEN) was analyzed. FISH for AR was successfully performed on samples from 60 out of 72 patients (83%). Increased AR copy number was detected in 40 out of 60 patients (67%). We have taken into account only cases presenting more than the median of CD133? in the entire group (C4 CD133? cells). In the group of 37 cases with more than four CD133? CTCs, 30 (81%) showed gains for AR whereas the remaining seven had no abnormality. FISH analysis for PTEN status assessment was performed on samples from 59 patients, 19 of whom showed B3 CD133? CTCs. PTEN gene status was available in 40 cases with more than four CD133? CTCs, 27 of whom (68%) showed loss of PTEN, 3 (8%) were polyploid for CEP10/PTEN and 10 (25%) showed no changes.
We performed FISH analysis on the basis of the patterns of the signals for CEPX/AR and CEP10/PTEN ( Table 2 ). The patterns of distribution of CD133? CTCs concerning AR relative gains, which are well known in prostate cancer, showed that among the 1846 CTCs analyzed for AR copy number (Table 3) , the majority (1562; 85%) showed normal patterns (1R1G) and 209 (11%) showed AR gains (2R2G). CTCs with trisomy or polyploidy patterns (3R3G or 4R4G) were observed in 33 CTCs (1.7%) and 39 (2.1%) showed a 2G C 4R pattern. CEP10/PTEN patterns of distribution were analyzed using FISH in all cases with (70%) were diploid for CEP10/PTEN, 372 (23%) showed PTEN loss and 114 (7%) showed polyploidy. Therefore, no abnormalities by CEPX/AR and CEP10/PTEN were shown in the majority of the CD133? CTCs. Regarding AR-V7 expression, Table 2 shows the distribution of cells in cases of AR-V7? versus AR-V7-negative. There are no differences in terms of CEPX/AR between the groups (16% gains in AR-V7 negative cells versus 13% gains in AR-V7? cells). For PTEN/CEP10 results, a higher number of cell deletion was observed in AR-V7-negative cells (24 vs. 18%), whereas among those that were AR-V7?, the number of cells with polyploidy patterns for PTEN was higher (10 vs. 6%).
Discussion
This study describes, for the first time, the feasibility of detecting AR-V7 expression in plasma (liquid biopsies) from patients with prostate cancer at different stages using an automated capillary nano-immunoassay ''WESTM'' (ProteinSimple). Previous studies have shown that detection of AR-V7 in CTCs from men with CRPC is associated with resistance to abiraterone and enzalutamide [2] , but not to taxane chemotherapy [2, 10] . These studies used a CTCenriched platform followed by multiplexed reverse transcription PCR to detect full-length androgen receptor and AR-V7 transcripts. However, this technique is difficult to implement in daily practice, and it is only able to detect AR-V7-positive patients if they have CTCs, so a high burden disease. The present study describes the possibility to detect ARV7 expression in different stages of prostate cancer from plasma, with a simpler technique. We observed AR-V7 expression in 29% of patients with prostate cancer. Of note, there was a high percentage of patients with CRPC, with metastatic disease, higher level of PSA, with a high Gleason score in the group of cases with positive expression of AR-V7. The poor prognosis of patients with AR-V7 expression (frequently associated with the acquisition of the CRPC-phenotype) is probably related to constitutive activity of ARV7 [11] [12] [13] . However, previous experimental evidence showed that AR-V7 is expressed in both prostate cancer cells and normal prostate epithelial cells [14] and AR-V7 is more frequently expressed in CRPC compared with hormone sensitive prostate cancer [13] , as we have shown in our preliminary study. The transcriptional activity of AR-V7 is not regulated by androgens or antiandrogens. Moreover, AR-V7 is significantly upregulated during progression of prostate cancer [15] and AR-V7 expression level is correlated with the risk of tumor recurrence after radical prostatectomy [16] . We have only 27 patients castration-naïve, and our results show that 29% of these patients showed expression of AR-V7 in plasma, before they became castration resistant. Therefore, AR-V7 may be a novel mechanism underlying ablation independence during progression of prostate cancer, which supports the suggestion that AR-V7 Total   Total cells  1846  1562 209  20  13  39  1620  1134 148  85  139  102  12   85%  11%  1%  1%  2%  70%  9%  5%  9%  6%  1% may serve as a prognostic and predictive biomarker in response to hormonal therapy [16] [17] [18] . What is more, detection of AR-V7 on CTCs has been shown to be associated with superior survival in patients with CRPC who received taxane-based treatment over patients that received hormonal therapy [19] . Previous studies have documented the presence of CD133? CTCs in samples from patients with advanced CRPC as well as from patients with localized prostate cancer after local therapy [4, 20] . Putative prostate cancer stem cells and other cancer stem cell populations express the stem cell-associated antigen CD133. We observed an association between CD133 expression, genomic changes for AR and PTEN with the presence of AR-V7 in the plasma of these patients. Indeed, 96% of our patients had detectable populations of CD133? CTCs, which is in line with results of previous studies [3] . The number of cells detected depended on the stage and the number of previous treatments (Table 3) . Regarding the expression of AR-V7, AR-V7? patients with tumors had a higher number of CD133? CTCs than AR-V7-negative patients.
Furthermore, in those AR-V7? cases, the median CD133? CTC count was higher in patients with CRPC as compared with patients with castration-sensitive tumors. The expression of the stemness antigen CD133 suggests that these cells may have acquired properties of stemness during their migration into the bloodstream. Indeed, evidence suggests that AR variants could contribute to progression of prostate cancer through induction of an epithelial-to-mesenchymal transition phenotype and acquisition of stem cell characteristics [21] . The genetic characterization of the CD133? population allows us to suggest that the acquisition or progression to a more aggressive phenotype was associated with the presence of genomic alterations for AR and PTEN gene in the ARV7? cases. All but one of the AR-V7? cases (CRPC or castration-sensitive) showed abnormalities in these genes.
Conclusions
Our results demonstrate the feasibility of assessing the presence of AR-V7 and the genomic characterization in a single-tube assay of CTCs from patients with prostate cancer. These findings lay the foundations for liquid biopsy as a means of obtaining biological data in a more convenient way for the patient. These data are needed for personalized treatment decisions, which can prevent patients from receiving inefficient systemic therapy.
